Hodson and Geddes' Cystic Fibrosis

Inbunden, Engelska, 2023

AvAndrew Bush,Margarida D. Amaral,Jane C. Davies,Nicholas J. Simmonds,Jennifer L. Taylor-Cousar,Sarath C. Ranganathan

3 979 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Cystic Fibrosis has seen dramatic advances in treatment since the last edition, including targeted cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators for most CFTR gene abnormalities. This new fifth edition is an update and expansion of the rapid clinical and scientific advances in improving prognosis, and the impact of COVID-19, all of which has transformed conventional models of care. It covers basic science, such as how detailed understanding of the biology of the CFTR gene and protein has led to novel and beneficial therapies, as well as all aspects of clinical management in high-, middle- and low-income settings and the voices of individuals with CF from across the world. It will be a useful reference for clinicians, including all levels of trainees, across the whole multidisciplinary team, scientists and students.Key Features• Follows an appealing organization of chapters, by developing fundamental knowledge of the reader before moving on to more complex or developing topics.• Presents a comprehensive, authoritative and up-to-date text, integrating fundamental science and clinical aspects of cystic fibrosis providing an attractive read for clinicians, trainee doctors and scientists.• Draws on global expertise and reflects best evidence-based practice from experts conducting cutting-edge clinical and basic science research from around the world.

Produktinformation

Utgivningsdatum2023-10-27
Mått210 x 280 x 46 mm
Vikt3 980 g
FormatInbunden
SpråkEngelska
Antal sidor746
Upplaga5
FörlagTaylor & Francis Ltd
ISBN9781032202204

Tillhör följande kategorier

Andrew Bush MD FHEA FRCP FRCPCH FERS FAPSR ATSFProfessor of Paediatrics and Paediatric Respirology, National Heart and Lung Institute, and Imperial Centre for Paediatrics and Child Health, Imperial CollegeConsultant Paediatric Chest Physician, Royal Brompton & Harefield NHS Foundation TrustNIHR Senior Investigator EmeritusMargarida D. AmaralProfessorBioISI – Biosystems & Integrative Sciences InstituteFaculty of Sciences, University of Lisboa, PortugalJane C. Davies Professor in Paediatric Respirology & Experimental Medicine.Imperial College LondonHonorary Consultant in Paediatric Respiratory MedicineRoyal Brompton Hospital, part of Guy’s & St Thomas’ NHS Foundation TrustLondonUnited KingdomNicholas Simmonds MD(Res) FRCP Associate Director | Consultant Respiratory Physician Adult Cystic Fibrosis Centre, Royal Brompton Hospital Professor of Practice (Respiratory Medicine) National Heart and Lung Institute, Imperial College London Adult Cystic Fibrosis Centre, Royal Brompton Hospital Sydney Street, London United KingdomJennifer L. Taylor-Cousar, MD, MSCS, ATSF President, Medical StaffMedical Director, Clinical Research ServicesCo-Director and CF TDC Director, Adult CF ProgramProfessor, Departments of Medicine and Pediatrics,Divisions of Pulmonary, Critical Care and Sleep Medicine and Pediatric Pulmonary Medicine Divisions of Pulmonary Sciences and Critical Care Medicine and Pediatric PulmonologyUniversity of Colorado Anschutz Medical CampusSarath Ranganathan MBChB MRCP FRCPH FRACP PhD FThorSoc ATSF Stevenson Chair and Head, Department of Paediatrics | Academic Director of Clinical Education Strategy and Risk University of Melbourne Consultant, Respiratory and Sleep Medicine | Royal Children’s Hospital Head, Respiratory Diseases Research Group | Infection and Immunity | Murdoch Children’s Research Institute

Ch 1 Journey from Macromolecular Pathology to Molecular TherapiesCh 2 Global Epidemiology of CF: High-Income and Low-/Middle-Income Countries (Global Harmonization Registry Countries)Ch 3 Voices of Patients and FamiliesCh 4 Patient OrganisationsCh 5 Molecular Biology of CFTR: From the Gene to the ProteinCh 6 Biology of the CF Airway EpitheliumCh 7 The Physiology of Epithelial Ion and Fluid Transport: Beyond CFTR ModulatorsCh 8 Inflammation in Cystic Fibrosis Ch 9 Model Organisms of Cystic FibrosisCh 10 Systems Biology and the New OmicsCh 11 Genotype: Phenotype CorrelationsCh 12 Gene Environment InteractionsCh 13 Demographic, Socioeconomic, and Environmental Contributions to Health in Cystic FibrosisCh 14 Drug Discovery Platforms for CFTR ModulatorsCh 15 CFTR Modulator Drug Discovery and Translation into the ClinicCh 16 Newborn and Carrier Screening for CFCh 17 Diagnostic Tests: Sweat Testing, Epithelial Potential Differences and Genetic TestingCh 18 Immediate Management of the Newly Screened Positive BabyCh 19 Diagnosis of the Symptomatic PatientCh 20 Blurred Boundaries: CRMS/CFSPID and CFTR Related DisordersCh 21 Respiratory Disease across the LifecourseCh 22 Respiratory Effects of the New CFTR ModulatorsCh 23 Epidemiology and Microbiology of Cystic Fibrosis Pulmonary InfectionsCh 24 New Methods for Detecting and Identifying BacteriaCh 25 Non-Tuberculous Mycobacterial Infections in Cystic FibrosisCh 26 Fungal Diseases in CFCh 27 Molecular Microbiology of the CF Gut and LungCh 28 Pulmonary Exacerbations in Cystic Fibrosis: Epidemiology, Treatment, Outcomes, and Future ResearchCh 29 Infection Prevention and Control in Cystic FibrosisCh 30 Technology in Cystic Fibrosis TherapiesCh 31 Upper Airway Disease in Cystic FibrosisCh 32 Gastrointestinal Disease in CFCh 33 Cystic Fibrosis Liver DiseaseCh 34 Cystic Fibrosis-Related DiabetesCh 35 Growth in Cystic Fibrosis: Is Chloride Transport the Key?Ch 36 Bone Disease in Cystic FibrosisCh 37 Cancer and Cystic FibrosisCh 38 Other Cystic Fibrosis-Related Diseases and ComplicationsCh 39 Extrapulmonary Benefits of the New CFTR Modulator DrugsCh 40 Sexual Health, Fertility, and Pregnancy in People with Cystic FibrosisCh 41 Mental Health Issues in Cystic FibrosisCh 42 Adherence and Self-Management in Cystic Fibrosis CareCh 43 TransplantationCh 44: Working with Cystic FibrosisCh 45 Growing Old with Cystic FibrosisCh 46 Imaging of Cystic Fibrosis Lung DiseaseCh 47 Lung Function Testing Including Multiple Breath WashoutCh 48 Infant Pulmonary Function TestsCh 49 Exercise Testing in Cystic FibrosisCh 50 Bronchoscopy and Bronchoalveolar Lavage in Cystic FibrosisCh 51 Patient-Derived Cell-Based Models for Theratyping and Individual CFTR Modulator AssessmentCh 52 Minimally Invasive Investigations for Biomarkers of Airways DiseaseCh 53 Currrent and Future Interventional Trial Designs to Support the CF Therapeutic PipelineCh 54 Gene and RNA-Bbased TherapiesCh 55 Cystic Fibrosis in Limited Resource SettingsCh 56 Traveling with Cystic FibrosisCh 57 Organisation of Cystic Fibrosis Centre CareCh 58 The Role of the CF Nurse SpecialistCh 60 The Role of the DietitianCh 61 The Role of the Pharmacist as Part of the Multidisciplinary Team Caring for CF PatientsCh 62 The Role of a Psychologist on the Cystic Fibrosis Care TeamCh 63 Adolescent Health and Transition in Cystic FibrosisCh 64 Palliative and Supportive CareCh 65 Using Registries and Databases to Drive up QualityCh 66 Digital Transformations within CF HealthcareCh 67 Personalized Medicine for Cystic Fibrosis in the 21st CenturyCh 68 CF Research Priorities for the Future